Asahi Kasei regains global rights to thrombomodulin through Artisan buyout
This article was originally published in Scrip
The pharma division of Japan's Asahi Kasei has bought out the private US venture Artisan Pharma, in which it was already an investor and to which it had licensed the recombinant human thrombomodulin-alfa product ART-123 for development outside Asia.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.